NEW YORK (Reuters) - Quest Diagnostics Inc, the world's largest provider of diagnostic testing services, is working with France's national health agency to build an expanded database for BRCA1 and ...

Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy Conclusion: In a clinical setting, we show a high demand ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...

ROCHESTER, Minn. — Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic ...

Medicare Part B covers various genetic tests for diagnosing genetic conditions, identifying cancer risks, and predicting medication responses if a doctor deems them medically necessary. The cost of ...